148 related articles for article (PubMed ID: 36482766)
1. Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis.
Kawada T; Yanagisawa T; Araki M; Pradere B; Shariat SF
Curr Opin Urol; 2023 May; 33(3):211-218. PubMed ID: 36482766
[TBL] [Abstract][Full Text] [Related]
2. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
Steinberg RL; Packiam VT; Thomas LJ; Brooks N; Vitale A; Mott SL; Crump T; Wang J; DeWolf WC; Lamm DL; Kates M; Hyndman ME; Kamat AM; Bivalacqua TJ; Nepple KG; O'Donnell MA
Urol Oncol; 2022 Jan; 40(1):9.e1-9.e7. PubMed ID: 34092482
[TBL] [Abstract][Full Text] [Related]
3. Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
McElree IM; Steinberg RL; Martin AC; Richards J; Mott SL; Gellhaus PT; Nepple KG; O'Donnell MA; Packiam VT
J Urol; 2022 Sep; 208(3):589-599. PubMed ID: 35892270
[TBL] [Abstract][Full Text] [Related]
4. Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study.
Pareek T; Parmar K; Sharma AP; Kumar S
Urol Int; 2022; 106(8):784-790. PubMed ID: 35654025
[TBL] [Abstract][Full Text] [Related]
5. Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.
Yim K; Melnick K; Mott SL; Carvalho FLF; Zafar A; Clinton TN; Mossanen M; Steele GS; Hirsch M; Rizzo N; Wu CL; Mouw KW; Wszolek M; Salari K; Feldman A; Kibel AS; O'Donnell MA; Preston MA
Urol Oncol; 2023 Nov; 41(11):458.e1-458.e7. PubMed ID: 37690933
[TBL] [Abstract][Full Text] [Related]
6. Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?
Abou Chakra M; Packiam VT; Duquesne I; Peyromaure M; McElree IM; O'Donnell MA
Expert Opin Pharmacother; 2024 Feb; 25(2):203-214. PubMed ID: 38264853
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer.
Chevuru PT; McElree IM; Mott SL; Steinberg RL; O'Donnell MA; Packiam VT
Urol Oncol; 2023 Mar; 41(3):148.e1-148.e7. PubMed ID: 36456454
[TBL] [Abstract][Full Text] [Related]
8. Sequential intravesical gemcitabine and docetaxel for treatment-naïve and previously treated intermediate-risk nonmuscle invasive bladder cancer.
McElree IM; Orzel J; Stubbee R; Steinberg RL; Mott SL; O'Donnell MA; Packiam VT
Urol Oncol; 2023 Dec; 41(12):485.e1-485.e7. PubMed ID: 37442741
[TBL] [Abstract][Full Text] [Related]
9. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
[TBL] [Abstract][Full Text] [Related]
10. Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis.
Bukavina L; Bell S; Packiam VT; Smaldone M; Abbosh P; Uzzo R; Kutikov A; Correa AF; Magee DE
Urol Oncol; 2023 Sep; 41(9):391.e1-391.e4. PubMed ID: 37127478
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis.
Kawada T; Yanagisawa T; Bekku K; Laukhtina E; von Deimling M; Chlosta M; Pradere B; Teoh JY; Babjuk M; Araki M; Shariat SF
Urol Oncol; 2023 Jun; 41(6):261-273. PubMed ID: 37137745
[TBL] [Abstract][Full Text] [Related]
12. Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer.
Kavoussi M; Nasrallah AA; Williams SB
Eur Urol; 2022 Dec; 82(6):659. PubMed ID: 36089530
[No Abstract] [Full Text] [Related]
13. Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols.
Ben-David R; Tillu N; Alerasool P; Bieber C; Ranti D; Tolani S; Eisenhauer J; Chung R; Lavallée E; Waingankar N; Attalla K; Wiklund P; Mehrazin R; Anderson CB; Sfakianos JP
World J Urol; 2024 May; 42(1):315. PubMed ID: 38734774
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer.
Daniels MJ; Barry E; Milbar N; Schoenberg M; Bivalacqua TJ; Sankin A; Kates M
Urol Oncol; 2020 Feb; 38(2):40.e17-40.e24. PubMed ID: 31473090
[TBL] [Abstract][Full Text] [Related]
15. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
16. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
17. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer.
McElree IM; Steinberg RL; Mott SL; O'Donnell MA; Packiam VT
JAMA Netw Open; 2023 Feb; 6(2):e230849. PubMed ID: 36853609
[TBL] [Abstract][Full Text] [Related]
19. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer.
Tan WS; McElree IM; Davaro F; Steinberg RL; Bree K; Navai N; Dinney CP; O'Donnell MA; Li R; Kamat AM; Packiam VT
Eur Urol Oncol; 2023 Oct; 6(5):531-534. PubMed ID: 37468392
[TBL] [Abstract][Full Text] [Related]
20. Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette-Guérin for the treatment of upper tract carcinoma in situ.
McElree IM; Mott SL; Hougen HY; Packiam VT; O'Donnell MA; Steinberg RL
Urol Oncol; 2024 Jul; 42(7):221.e9-221.e16. PubMed ID: 38609747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
